. Author manuscript; available in PMC: 2012 Apr 1.

Published in final edited form as: Drug Discov Today Dis Models. 2011 Spring;8(1):37–46. doi: 10.1016/j.ddmod.2011.05.002

Table I.

Extracellular Domain Receptor Cleavage and Cell Dysfunctions in the SHR

Receptor Type	Cell - Organ Dysfunction
β₂ Adrenergic Receptor	Arteriolar vasoconstriction and central blood pressure elevation – hypertension; (66)
Insulin Receptor -α	Insulin Resistance with reduced glucose transport - Type 2 diabetes mellitus; (43)
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)	Endothelial apoptosis and elevated endothelial permeability - Capillary rarefaction; (46,48)
Formyl Peptide Receptor (FPR)	Reduced response to formyl peptide and fluid shear stress on leukocytes – Suppression of fluid shear response and elevated capillary hemodynamic resistance; (72)
β₂ Integrin Adhesion Molecule (CD18)	Attenuated leukocyte-endothelial interaction - Immune suppression and also resistance to inflammatory stimuli (43)
Tight Junction Proteins: Occludin and Claudin - 5	Increased endothelial permeability; (74)
Inter-Cellular Adhesion Molecule 1 (ICAM-1, CD54)	Proteolytic cleavage of the extracellular domain of ICAM-1 and accumulation in kidney glomeruli; (63)
Serotonin 5HT-1A receptor	Reduced sleep quality – Insomnia; (77)